Fundraising Fox
Oban BioPharma
1 known investors
Find your way into Oban BioPharma
Sign up to see every warm intro you have to Oban BioPharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Oban BioPharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Oban Biopharma develops allosteric GPCR-targeted therapeutics for metabolic and CNS/neuropsychiatric diseases, using computational structural and chemotype analysis combined with AI-based druggability filters to identify drug candidates. Its pipeline focuses on allosteric modulators of clinically validated GPCR targets intended to offer efficacy with fewer side effects than traditional orthosteric drugs.
Founders & leadership
Investors · 1
Related companies · 2
Abalone BioAbalone Bio develops activating antibodies (agonists) targeting hard-to-drug receptors such as G-protein coupled receptors, using engineered cells to measure antibody pharmacological activity at high throughput combined with machine learning. Its initial focus is cell-specific antibody drugs for obesity and metabolic disease aimed at avoiding the GI side effects associated with GLP-1 therapies.
Abeona TherapeuticsAbeona Therapeutics is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases with high unmet need, including its approved product ZEVASKYN and its lead PSMA-targeted T cell therapy ABO-701 for advanced prostate cancer. It uses ex vivo gene therapy, viral vector, and synthetic immune receptor T cell (SIR-T) technologies to serve patients with genetic diseases and solid tumors.
Companies working in the same space as Oban BioPharma.
Frequently asked questions
- What does Oban BioPharma do?
- Oban Biopharma develops allosteric GPCR-targeted therapeutics for metabolic and CNS/neuropsychiatric diseases, using computational structural and chemotype analysis combined with AI-based druggability filters to identify drug candidates. Its pipeline focuses on allosteric modulators of clinically validated GPCR targets intended to offer efficacy with fewer side effects than traditional orthosteric drugs.
- Who founded Oban BioPharma?
- Oban BioPharma was founded by Derek Chalmers.
- Who are Oban BioPharma's investors?
- Oban BioPharma's investors include Connecticut Innovations.